Physician profile
Arkady Broder
NPI 1336307529
$21,198.68
in general payments reported to CMS, 2019-2025
18 companies · $8,877 in 2025
The $8,877 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,090 · 2020: $53.98 · 2021: $125 · 2022: $434 · 2023: $2,747 · 2024: $4,872 · 2025: $8,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,335 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,950 · Food and Beverage: $2,116 · Education: $94.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,335.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,950.00 |
| Food and Beverage | $2,116.07 |
| Education | $94.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11,277.17 | 2019-2025 | Tremfya, Stelara |
| Olympus America INC. | $6,993.83 | 2019-2025 | Visiglide |
| Abbvie INC. | $1,445.17 | 2019-2025 | Skyrizi, Rinvoq |
| Boston Scientific Corporation | $525.27 | 2019-2025 | General - Biliary Devices, Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $447.49 | 2023-2025 | Entyvio, Gattex |
| Integra Lifesciences Corporation | $174.32 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Lilly USA, LLC | $70.92 | 2024-2025 | Omvoh |
| Celgene Corporation | $58.99 | 2021-2023 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $47.89 | 2025 | |
| Ferring Pharmaceuticals INC. | $31.58 | 2023 | Rebyota |
| Medtronic, INC. | $22.99 | 2022 | |
| Merck Sharp & Dohme LLC | $18.07 | 2024 | Dificid |
| Capsovision, INC. | $17.31 | 2025 | Capsocam Plus |
| Pfizer INC. | $15.51 | 2023 | |
| Amgen INC. | $14.13 | 2023 | Amjevita |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $14.12 | 2023 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $13.44 | 2023 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Broder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.